Alectinib
Alectinib 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Non-small Cell Lung Cancer、Anaplastic Lymphoma Kinase-positive。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
23 项
全球在招研究
4 项
已进入 III/IV 期
24 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Nuvalent Inc.
- Centre Leon Berard
- Cancer Research UK
- Genentech, Inc.
- Memorial Sloan Kettering Cancer Center
- Hunan Province Tumor Hospital
- University Medical Center Groningen
- Karolinska University Hospital
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
法国、英国、美国、中国、荷兰、澳大利亚、比利时、加拿大、德国、意大利、日本、Singapore
正在招募患者的 Alectinib 研究
A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.
II 期招募中法国NCT04116541DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
II 期 / III 期招募中英国NCT05770037A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
II 期招募中美国NCT04302025A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)
I 期招募中美国NCT07001384ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma
II 期招募中中国NCT05014464Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels
IV 期招募中法国荷兰NCT05525338DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
II 期 / III 期招募中英国NCT05722886A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
I 期 / II 期招募中美国澳大利亚比利时加拿大NCT05384626Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK
II 期招募中中国NCT05266846Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
III 期招募中美国Argentina澳大利亚奥地利NCT06765109Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB)
不适用招募中瑞典NCT05724004Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
II 期招募中挪威NCT05725200PLATFORM Study of Precision Medicine for Rare Tumors
II 期招募中中国NCT04423185Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
II 期招募中中国NCT04322890The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
II 期招募中芬兰NCT05159245Multi Omics Molecular Characteristics and Immunophenotyping of Lung Signet Ring Cell Carcinoma
不适用招募中中国NCT07207278OBSERVE: A Pilot Study Of Omission Of Brain Metastasis Stereotactic Radiosurgery Following Resection With CNS-Active Systemic Therapy
I 期招募中美国NCT07655583Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements
I 期 / II 期招募中美国NCT05987644Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
不适用招募中中国NCT06862869The Drug Rediscovery Protocol (DRUP Trial)
II 期招募中荷兰NCT02925234Alectinib Pharmacokinetic in Patients With NSCLC
I 期 / II 期招募中MexicoNCT05713006ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling
II 期招募中丹麦NCT04341181Improving Public Cancer Care by Implementing Precision Medicine in Norway
II 期招募中挪威NCT04817956
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。